Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NCT07906665Phase 1Not yet recruiting
- Sponsor
- Sachi Bio
- Start
- Jan 2027
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NI-112 in amyotrophic lateral sclerosis (ALS) (8 arms), sponsored by Sachi Bio. Primary endpoints: Treatment-Emergent Adverse Events, Treatment-Emergent Serious Adverse Events and 6 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
NI-112
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07906665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07906665.